mirror of
https://github.com/stleary/JSON-java.git
synced 2025-08-02 11:05:28 -04:00
Reduced Test code length by using resources
This commit is contained in:
Dean
parent
fa457a4113
commit
4a8ff28fd8
File diff suppressed because it is too large
Load Diff
189
src/test/resources/Issue593.json
Normal file
189
src/test/resources/Issue593.json
Normal file
@ -0,0 +1,189 @@
|
||||
{
|
||||
"clinical_study": {
|
||||
"brief_summary": {
|
||||
"textblock": "CLEAR SYNERGY is an international multi center 2x2 randomized placebo controlled trial of"
|
||||
},
|
||||
"brief_title": "CLEAR SYNERGY Neutrophil Substudy",
|
||||
"overall_status": "Recruiting",
|
||||
"eligibility": {
|
||||
"study_pop": {
|
||||
"textblock": "Patients who are randomized to the drug RCT portion of the CLEAR SYNERGY (OASIS 9) trial"
|
||||
},
|
||||
"minimum_age": "19 Years",
|
||||
"sampling_method": "Non-Probability Sample",
|
||||
"gender": "All",
|
||||
"criteria": {
|
||||
"textblock": "Inclusion Criteria:"
|
||||
},
|
||||
"healthy_volunteers": "No",
|
||||
"maximum_age": "110 Years"
|
||||
},
|
||||
"number_of_groups": "2",
|
||||
"source": "NYU Langone Health",
|
||||
"location_countries": {
|
||||
"country": "United States"
|
||||
},
|
||||
"study_design_info": {
|
||||
"time_perspective": "Prospective",
|
||||
"observational_model": "Other"
|
||||
},
|
||||
"last_update_submitted_qc": "September 10, 2019",
|
||||
"intervention_browse": {
|
||||
"mesh_term": "Colchicine"
|
||||
},
|
||||
"official_title": "Studies on the Effects of Colchicine on Neutrophil Biology in Acute Myocardial Infarction: A Substudy of the CLEAR SYNERGY (OASIS 9) Trial",
|
||||
"primary_completion_date": {
|
||||
"type": "Anticipated",
|
||||
"content": "February 1, 2021"
|
||||
},
|
||||
"sponsors": {
|
||||
"lead_sponsor": {
|
||||
"agency_class": "Other",
|
||||
"agency": "NYU Langone Health"
|
||||
},
|
||||
"collaborator": [
|
||||
{
|
||||
"agency_class": "Other",
|
||||
"agency": "Population Health Research Institute"
|
||||
},
|
||||
{
|
||||
"agency_class": "NIH",
|
||||
"agency": "National Heart, Lung, and Blood Institute (NHLBI)"
|
||||
}
|
||||
]
|
||||
},
|
||||
"overall_official": {
|
||||
"role": "Principal Investigator",
|
||||
"affiliation": "NYU School of Medicine",
|
||||
"last_name": "Binita Shah, MD"
|
||||
},
|
||||
"overall_contact_backup": {
|
||||
"last_name": "Binita Shah, MD"
|
||||
},
|
||||
"condition_browse": {
|
||||
"mesh_term": [
|
||||
"Myocardial Infarction",
|
||||
"ST Elevation Myocardial Infarction",
|
||||
"Infarction"
|
||||
]
|
||||
},
|
||||
"overall_contact": {
|
||||
"phone": "646-501-9648",
|
||||
"last_name": "Fatmira Curovic",
|
||||
"email": "fatmira.curovic@nyumc.org"
|
||||
},
|
||||
"responsible_party": {
|
||||
"responsible_party_type": "Principal Investigator",
|
||||
"investigator_title": "Assistant Professor of Medicine",
|
||||
"investigator_full_name": "Binita Shah",
|
||||
"investigator_affiliation": "NYU Langone Health"
|
||||
},
|
||||
"study_first_submitted_qc": "March 12, 2019",
|
||||
"start_date": {
|
||||
"type": "Actual",
|
||||
"content": "March 4, 2019"
|
||||
},
|
||||
"has_expanded_access": "No",
|
||||
"study_first_posted": {
|
||||
"type": "Actual",
|
||||
"content": "March 14, 2019"
|
||||
},
|
||||
"arm_group": [
|
||||
{
|
||||
"arm_group_label": "Colchicine"
|
||||
},
|
||||
{
|
||||
"arm_group_label": "Placebo"
|
||||
}
|
||||
],
|
||||
"primary_outcome": {
|
||||
"measure": "soluble L-selectin",
|
||||
"time_frame": "between baseline and 3 months",
|
||||
"description": "Change in soluble L-selectin between baseline and 3 mo after STEMI in the placebo vs. colchicine groups."
|
||||
},
|
||||
"secondary_outcome": [
|
||||
{
|
||||
"measure": "Other soluble markers of neutrophil activity",
|
||||
"time_frame": "between baseline and 3 months",
|
||||
"description": "Other markers of neutrophil activity will be evaluated at baseline and 3 months after STEMI (myeloperoxidase, matrix metalloproteinase-9, neutrophil gelatinase-associated lipocalin, neutrophil elastase, intercellular/vascular cellular adhesion molecules)"
|
||||
},
|
||||
{
|
||||
"measure": "Markers of systemic inflammation",
|
||||
"time_frame": "between baseline and 3 months",
|
||||
"description": "Markers of systemic inflammation will be evaluated at baseline and 3 months after STEMI (high sensitive CRP, IL-1β)"
|
||||
},
|
||||
{
|
||||
"measure": "Neutrophil-driven responses that may further propagate injury",
|
||||
"time_frame": "between baseline and 3 months",
|
||||
"description": "Neutrophil-driven responses that may further propagate injury will be evaluated at baseline and 3 months after STEMI (neutrophil extracellular traps, neutrophil-derived microparticles)"
|
||||
}
|
||||
],
|
||||
"oversight_info": {
|
||||
"is_fda_regulated_drug": "No",
|
||||
"is_fda_regulated_device": "No",
|
||||
"has_dmc": "No"
|
||||
},
|
||||
"last_update_posted": {
|
||||
"type": "Actual",
|
||||
"content": "September 12, 2019"
|
||||
},
|
||||
"id_info": {
|
||||
"nct_id": "NCT03874338",
|
||||
"org_study_id": "18-01323",
|
||||
"secondary_id": "1R01HL146206"
|
||||
},
|
||||
"enrollment": {
|
||||
"type": "Anticipated",
|
||||
"content": "670"
|
||||
},
|
||||
"study_first_submitted": "March 12, 2019",
|
||||
"condition": [
|
||||
"Neutrophils.Hypersegmented | Bld-Ser-Plas",
|
||||
"STEMI - ST Elevation Myocardial Infarction"
|
||||
],
|
||||
"study_type": "Observational",
|
||||
"required_header": {
|
||||
"download_date": "ClinicalTrials.gov processed this data on July 19, 2020",
|
||||
"link_text": "Link to the current ClinicalTrials.gov record.",
|
||||
"url": "https://clinicaltrials.gov/show/NCT03874338"
|
||||
},
|
||||
"last_update_submitted": "September 10, 2019",
|
||||
"completion_date": {
|
||||
"type": "Anticipated",
|
||||
"content": "February 1, 2022"
|
||||
},
|
||||
"location": {
|
||||
"contact": {
|
||||
"phone": "646-501-9648",
|
||||
"last_name": "Fatmira Curovic",
|
||||
"email": "fatmira.curovic@nyumc.org"
|
||||
},
|
||||
"facility": {
|
||||
"address": {
|
||||
"zip": "10016",
|
||||
"country": "United States",
|
||||
"city": "New York",
|
||||
"state": "New York"
|
||||
},
|
||||
"name": "NYU School of Medicine"
|
||||
},
|
||||
"status": "Recruiting",
|
||||
"contact_backup": {
|
||||
"last_name": "Binita Shah, MD"
|
||||
}
|
||||
},
|
||||
"intervention": {
|
||||
"intervention_type": "Drug",
|
||||
"arm_group_label": [
|
||||
"Colchicine",
|
||||
"Placebo"
|
||||
],
|
||||
"description": "Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.",
|
||||
"intervention_name": "Colchicine Pill"
|
||||
},
|
||||
"patient_data": {
|
||||
"sharing_ipd": "No"
|
||||
},
|
||||
"verification_date": "September 2019"
|
||||
}
|
||||
}
|
||||
169
src/test/resources/Issue593.xml
Normal file
169
src/test/resources/Issue593.xml
Normal file
@ -0,0 +1,169 @@
|
||||
<?xml version="1.0" encoding="UTF-8"?>
|
||||
<clinical_study>
|
||||
<!-- This xml conforms to an XML Schema at:
|
||||
https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
|
||||
<required_header>
|
||||
<download_date>ClinicalTrials.gov processed this data on July 19, 2020</download_date>
|
||||
<link_text>Link to the current ClinicalTrials.gov record.</link_text>
|
||||
<url>https://clinicaltrials.gov/show/NCT03874338</url>
|
||||
</required_header>
|
||||
<id_info>
|
||||
<org_study_id>18-01323</org_study_id>
|
||||
<secondary_id>1R01HL146206</secondary_id>
|
||||
<nct_id>NCT03874338</nct_id>
|
||||
</id_info>
|
||||
<brief_title>CLEAR SYNERGY Neutrophil Substudy</brief_title>
|
||||
<official_title>Studies on the Effects of Colchicine on Neutrophil Biology in Acute Myocardial Infarction: A Substudy of the CLEAR SYNERGY (OASIS 9) Trial</official_title>
|
||||
<sponsors>
|
||||
<lead_sponsor>
|
||||
<agency>NYU Langone Health</agency>
|
||||
<agency_class>Other</agency_class>
|
||||
</lead_sponsor>
|
||||
<collaborator>
|
||||
<agency>Population Health Research Institute</agency>
|
||||
<agency_class>Other</agency_class>
|
||||
</collaborator>
|
||||
<collaborator>
|
||||
<agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
|
||||
<agency_class>NIH</agency_class>
|
||||
</collaborator>
|
||||
</sponsors>
|
||||
<source>NYU Langone Health</source>
|
||||
<oversight_info>
|
||||
<has_dmc>No</has_dmc>
|
||||
<is_fda_regulated_drug>No</is_fda_regulated_drug>
|
||||
<is_fda_regulated_device>No</is_fda_regulated_device>
|
||||
</oversight_info>
|
||||
<brief_summary>
|
||||
<textblock>
|
||||
CLEAR SYNERGY is an international multi center 2x2 randomized placebo controlled trial of
|
||||
</textblock>
|
||||
</brief_summary>
|
||||
<overall_status>Recruiting</overall_status>
|
||||
<start_date type="Actual">March 4, 2019</start_date>
|
||||
<completion_date type="Anticipated">February 1, 2022</completion_date>
|
||||
<primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
|
||||
<study_type>Observational</study_type>
|
||||
<has_expanded_access>No</has_expanded_access>
|
||||
<study_design_info>
|
||||
<observational_model>Other</observational_model>
|
||||
<time_perspective>Prospective</time_perspective>
|
||||
</study_design_info>
|
||||
<primary_outcome>
|
||||
<measure>soluble L-selectin</measure>
|
||||
<time_frame>between baseline and 3 months</time_frame>
|
||||
<description>Change in soluble L-selectin between baseline and 3 mo after STEMI in the placebo vs. colchicine groups.</description>
|
||||
</primary_outcome>
|
||||
<secondary_outcome>
|
||||
<measure>Other soluble markers of neutrophil activity</measure>
|
||||
<time_frame>between baseline and 3 months</time_frame>
|
||||
<description>Other markers of neutrophil activity will be evaluated at baseline and 3 months after STEMI (myeloperoxidase, matrix metalloproteinase-9, neutrophil gelatinase-associated lipocalin, neutrophil elastase, intercellular/vascular cellular adhesion molecules)</description>
|
||||
</secondary_outcome>
|
||||
<secondary_outcome>
|
||||
<measure>Markers of systemic inflammation</measure>
|
||||
<time_frame>between baseline and 3 months</time_frame>
|
||||
<description>Markers of systemic inflammation will be evaluated at baseline and 3 months after STEMI (high sensitive CRP, IL-1β)</description>
|
||||
</secondary_outcome>
|
||||
<secondary_outcome>
|
||||
<measure>Neutrophil-driven responses that may further propagate injury</measure>
|
||||
<time_frame>between baseline and 3 months</time_frame>
|
||||
<description>Neutrophil-driven responses that may further propagate injury will be evaluated at baseline and 3 months after STEMI (neutrophil extracellular traps, neutrophil-derived microparticles)</description>
|
||||
</secondary_outcome>
|
||||
<number_of_groups>2</number_of_groups>
|
||||
<enrollment type="Anticipated">670</enrollment>
|
||||
<condition>Neutrophils.Hypersegmented | Bld-Ser-Plas</condition>
|
||||
<condition>STEMI - ST Elevation Myocardial Infarction</condition>
|
||||
<arm_group>
|
||||
<arm_group_label>Colchicine</arm_group_label>
|
||||
</arm_group>
|
||||
<arm_group>
|
||||
<arm_group_label>Placebo</arm_group_label>
|
||||
</arm_group>
|
||||
<intervention>
|
||||
<intervention_type>Drug</intervention_type>
|
||||
<intervention_name>Colchicine Pill</intervention_name>
|
||||
<description>Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.</description>
|
||||
<arm_group_label>Colchicine</arm_group_label>
|
||||
<arm_group_label>Placebo</arm_group_label>
|
||||
</intervention>
|
||||
<eligibility>
|
||||
<study_pop>
|
||||
<textblock>
|
||||
Patients who are randomized to the drug RCT portion of the CLEAR SYNERGY (OASIS 9) trial
|
||||
</textblock>
|
||||
</study_pop>
|
||||
<sampling_method>Non-Probability Sample</sampling_method>
|
||||
<criteria>
|
||||
<textblock>
|
||||
Inclusion Criteria:
|
||||
</textblock>
|
||||
</criteria>
|
||||
<gender>All</gender>
|
||||
<minimum_age>19 Years</minimum_age>
|
||||
<maximum_age>110 Years</maximum_age>
|
||||
<healthy_volunteers>No</healthy_volunteers>
|
||||
</eligibility>
|
||||
<overall_official>
|
||||
<last_name>Binita Shah, MD</last_name>
|
||||
<role>Principal Investigator</role>
|
||||
<affiliation>NYU School of Medicine</affiliation>
|
||||
</overall_official>
|
||||
<overall_contact>
|
||||
<last_name>Fatmira Curovic</last_name>
|
||||
<phone>646-501-9648</phone>
|
||||
<email>fatmira.curovic@nyumc.org</email>
|
||||
</overall_contact>
|
||||
<overall_contact_backup>
|
||||
<last_name>Binita Shah, MD</last_name>
|
||||
</overall_contact_backup>
|
||||
<location>
|
||||
<facility>
|
||||
<name>NYU School of Medicine</name>
|
||||
<address>
|
||||
<city>New York</city>
|
||||
<state>New York</state>
|
||||
<zip>10016</zip>
|
||||
<country>United States</country>
|
||||
</address>
|
||||
</facility>
|
||||
<status>Recruiting</status>
|
||||
<contact>
|
||||
<last_name>Fatmira Curovic</last_name>
|
||||
<phone>646-501-9648</phone>
|
||||
<email>fatmira.curovic@nyumc.org</email>
|
||||
</contact>
|
||||
<contact_backup>
|
||||
<last_name>Binita Shah, MD</last_name>
|
||||
</contact_backup>
|
||||
</location>
|
||||
<location_countries>
|
||||
<country>United States</country>
|
||||
</location_countries>
|
||||
<verification_date>September 2019</verification_date>
|
||||
<study_first_submitted>March 12, 2019</study_first_submitted>
|
||||
<study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
|
||||
<study_first_posted type="Actual">March 14, 2019</study_first_posted>
|
||||
<last_update_submitted>September 10, 2019</last_update_submitted>
|
||||
<last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
|
||||
<last_update_posted type="Actual">September 12, 2019</last_update_posted>
|
||||
<responsible_party>
|
||||
<responsible_party_type>Principal Investigator</responsible_party_type>
|
||||
<investigator_affiliation>NYU Langone Health</investigator_affiliation>
|
||||
<investigator_full_name>Binita Shah</investigator_full_name>
|
||||
<investigator_title>Assistant Professor of Medicine</investigator_title>
|
||||
</responsible_party>
|
||||
<condition_browse>
|
||||
<!-- CAUTION: The following MeSH terms are assigned with an imperfect algorithm -->
|
||||
<mesh_term>Myocardial Infarction</mesh_term>
|
||||
<mesh_term>ST Elevation Myocardial Infarction</mesh_term>
|
||||
<mesh_term>Infarction</mesh_term>
|
||||
</condition_browse>
|
||||
<intervention_browse>
|
||||
<!-- CAUTION: The following MeSH terms are assigned with an imperfect algorithm -->
|
||||
<mesh_term>Colchicine</mesh_term>
|
||||
</intervention_browse>
|
||||
<patient_data>
|
||||
<sharing_ipd>No</sharing_ipd>
|
||||
</patient_data>
|
||||
<!-- Results have not yet been posted for this study -->
|
||||
</clinical_study>
|
||||
Loading…
x
Reference in New Issue
Block a user